Date: Tuesday 21 May 2013
LONDON (ShareCast) - Ronald Goode, a non-Executive Director of Hikma Pharmaceuticals, has disposed of 5,700 shares at 983.00p each.
The £56,031 sale comes less than a week after the company upgraded its 2013 revenue growth forecast following a strong start to the year.
In an announcment released May 16th, the group told investors it expects revenue to rise 13% this year, up from its previous guidance of 10%, driven by the performance of Branded and Injectables and Generics businesses in the year-to-date.
The Branded and Injectables unit is on track to meet the firm’s full-year guidance, while the Generics arm is continuing to benefit from its doxycycline product which is delivering revenue ahead of forecasts.
Branded revenue is expected to increase 11% in 2013, with a slight improvement in adjusted operating margin.
Goode now owns 17,000 shares.
Top Director Buys
Symphony International Holdings Ltd. (SIHL)
Amount purchased: 500,000 @ $0.78
Director name: Mr Anil Thadani
Value: $388,750
Symphony International Holdings Ltd. (SIHL)
Director name: Mr Anil Thadani
Amount purchased: 30,000 @ $0.76
Value: $22,800
Xchanging (XCH)
Director name: Mr Bill Thomas
Amount purchased: 14,289 @ 139.97p
Value: £20,000
Zotefoams (ZTF)
Director name: Ms Marie-Louise Clayton
Amount purchased: 8,000 @ 195.00p
Value: £15,600
JPMorgan Overseas Inv Trust (JMO)
Director name: Mr Jonathan Carey
Amount purchased: 1,500 @ 923.00p
Value: £13,845
JPMorgan Claverhouse Inv Trust (JCH)
Director name: Mr Andrew L Sutch
Amount purchased: 2,196 @ 521.39p
Value: £11,450
Top Director Sells
Sirius Minerals (SXX)
Director name: Mr Jason Murray
Amount sold: 2,166,667 @ 23.00p
Value: £498,333
Spectris (SXS)
Director name: Mr James Webster
Amount sold: 19,821 @ 2,129.31p
Value: £422,051
Hikma Pharmaceuticals (HIK)
Director name: Dr Ronald Goode
Amount sold: 5,700 @ 983.00p
Value: £56,031
NR
Email this article to a friend
or share it with one of these popular networks: